Teleflex(US:TFX) ZACKS·2025-02-27 15:36Core Insights - Teleflex reported revenue of $795.41 million for Q4 2024, a year-over-year increase of 2.8%, with an EPS of $3.89 compared to $3.38 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $813.53 million by 2.23%, while the EPS exceeded the consensus estimate of $3.86 by 0.78% [1] Financial Performance - The company’s shares returned -1.6% over the past month, slightly outperforming the Zacks S&P 500 composite's -2.2% change [3] - Teleflex holds a Zacks Rank 4 (Sell), indicating potential underperformance against the broader market in the near term [3] Geographic Revenue Breakdown - Americas revenue reached $540.80 million, exceeding the average estimate of $468.16 million by 20% year-over-year [4] - Asia revenue was $93.60 million, below the average estimate of $99.25 million [4] - EMEA revenue totaled $161 million, slightly below the average estimate of $164.54 million [4] Segment Revenue Analysis - Interventional revenues were $160.40 million, surpassing the average estimate of $158.48 million, reflecting an 18.3% year-over-year increase [4] - Interventional Urology revenues were $84.90 million, falling short of the average estimate of $92.23 million, marking an 8.7% decline year-over-year [4] - OEM revenues were $85.40 million, slightly above the average estimate of $84.13 million, with a year-over-year increase of 3.4% [4] - Vascular Access revenues were $189.30 million, below the average estimate of $201.17 million, but showing a 1.4% increase year-over-year [4] - Anesthesia revenues were $95.30 million, below the average estimate of $104.17 million, reflecting a 3% decline year-over-year [4] - Other revenues were $58.20 million, exceeding the average estimate of $55.18 million, but showing a 14.7% decline year-over-year [4] - Surgical revenues were $121.90 million, above the average estimate of $118.18 million, with an 11.2% year-over-year increase [4]